Latest Period
Q4 2025
Security Snapshot
Minerva Neurosciences, Inc. - Common Stock, par value $0.0001 per share (NERV) Institutional Ownership
CUSIP: 603380205
13F Institutional Holders and Ownership History from Q2 2022 to Q1 2026
Institutions Reporting
29
Shares (Excl. Options)
23,063,409
Price
$4.02
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- NERV on Nasdaq
- Shares outstanding
- 45,675,986
- Price per share
- $6.02
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 23,063,409
- Total reported value
- $90,576,655
- % of total 13F portfolios
- 0%
- Share change
- +19,428,234
- Value change
- +$76,545,252
- Number of holders
- 29
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- NERV - Minerva Neurosciences, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 603380205.
- 29 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 29 to 4 between Q4 2025 and Q1 2026.
- Reported value moved from $90,576,655 to $644,686.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 29 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 603380205?
CUSIP 603380205 identifies NERV - Minerva Neurosciences, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 603380205:
Significant Owners of Minerva Neurosciences, Inc. - Common Stock, par value $0.0001 per share (NERV) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FEDERATED HERMES, INC. | 20% | +2.8% | $35,502,800 | +$30,394,980 | 9,392,275 | +595% | Federated Hermes, Inc. | 22 Dec 2025 |
| Vivo Opportunity Fund Holdings, L.P. | 10% | $32,476,142 | 8,591,572 | Vivo Opportunity Fund Holdings, L.P. | 23 Dec 2025 | |||
| Coastlands Capital LP | 10% | $18,571,536 | 4,563,031 | Coastlands Capital LP | 13 Feb 2026 | |||
| Farallon Capital Partners, L.P. | 10% | 0% | $18,250,213 | 4,539,854 | 0% | Dapice Joshua J. | 31 Dec 2025 | |
| Logos Global Management LP | 9.9% | $18,407,093 | 4,435,444 | Logos Global Management LP | 23 Dec 2025 | |||
| BALYASNY ASSET MANAGEMENT L.P. | 10% | $17,970,807 | 4,330,315 | Balyasny Asset Management L.P. | 31 Dec 2025 | |||
| Adage Capital Management, L.P. | 6.4% | $11,777,700 | 2,838,000 | Adage Capital Management, L.P. | 31 Dec 2025 |
As of 31 Dec 2025, 29 institutional investors reported holding 23,063,409 shares of Minerva Neurosciences, Inc. - Common Stock, par value $0.0001 per share (NERV). This represents 50% of the company’s total 45,675,986 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Minerva Neurosciences, Inc. - Common Stock, par value $0.0001 per share (NERV) together control 50% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FEDERATED HERMES, INC. | 12% | 5,371,775 | +298% | 0.03% | $19,456,450 |
| Vivo Capital, LLC | 9.5% | 4,322,747 | 1.1% | $17,377,443 | |
| Logos Global Management LP | 7.2% | 3,311,000 | 0.89% | $13,310,220 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.2% | 2,838,000 | 0.02% | $11,408,760 | |
| FARALLON CAPITAL MANAGEMENT LLC | 5.2% | 2,365,000 | 0.05% | $9,507,300 | |
| Ally Bridge Group (NY) LLC | 3.6% | 1,655,500 | 11% | $6,655,110 | |
| Spruce Street Capital LP | 3.6% | 1,655,500 | 0% | 2.2% | $6,655,110 |
| ACUTA CAPITAL PARTNERS, LLC | 1.6% | 709,500 | 1.9% | $2,852,190 | |
| VANGUARD GROUP INC | 0.55% | 252,029 | 0% | 0% | $1,013,156 |
| RENAISSANCE TECHNOLOGIES LLC | 0.33% | 149,200 | +28% | 0% | $599,784 |
| MILLENNIUM MANAGEMENT LLC | 0.3% | 137,911 | 0% | $554,402 | |
| BlackRock, Inc. | 0.16% | 72,669 | 0% | 0% | $292,129 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.15% | 69,919 | -7.5% | 0% | $281,133 |
| Apella Capital, LLC | 0.09% | 42,380 | +7.8% | 0% | $170,368 |
| Lion Point Capital, LP | 0.08% | 35,000 | 0.73% | $140,700 | |
| STATE STREET CORP | 0.05% | 24,019 | +45% | 0% | $96,556 |
| TWO SIGMA INVESTMENTS, LP | 0.05% | 22,294 | 0% | $89,622 | |
| MORGAN STANLEY | 0.02% | 11,055 | +0.43% | 0% | $44,441 |
| ACADIAN ASSET MANAGEMENT LLC | 0.02% | 10,579 | -39% | 0% | $42,000 |
| ROYAL BANK OF CANADA | 0% | 2,240 | -7.8% | 0% | $9,000 |
| UBS Group AG | 0% | 1,807 | +17970% | 0% | $7,264 |
| DEUTSCHE BANK AG\ | 0% | 1,500 | 0% | $6,030 | |
| Tower Research Capital LLC (TRC) | 0% | 501 | -63% | 0% | $2,014 |
| CWM, LLC | 0% | 420 | 0% | 0% | $2,000 |
| Larson Financial Group LLC | 0% | 400 | 0% | $1,608 |
Institutional Holders of Minerva Neurosciences, Inc. - Common Stock, par value $0.0001 per share (NERV) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 102,058 | $644,686 | +$357,956 | $6.02 | 4 |
| 2025 Q4 | 23,063,409 | $90,576,655 | +$76,545,252 | $4.02 | 29 |
| 2025 Q3 | 1,979,675 | $4,208,645 | +$81,860 | $2.10 | 22 |
| 2025 Q2 | 1,944,466 | $3,341,879 | -$12,369 | $1.72 | 18 |
| 2025 Q1 | 1,951,817 | $3,310,087 | -$310,831 | $1.70 | 19 |
| 2024 Q4 | 2,085,897 | $4,630,050 | -$81,975 | $2.22 | 21 |
| 2024 Q3 | 2,118,026 | $5,654,665 | +$83,536 | $2.67 | 19 |
| 2024 Q2 | 2,086,302 | $6,654,936 | -$42,908 | $3.19 | 20 |
| 2024 Q1 | 2,099,790 | $5,416,495 | -$2,569,915 | $2.58 | 20 |
| 2023 Q4 | 2,415,482 | $14,854,825 | +$68,371 | $6.15 | 19 |
| 2023 Q3 | 2,403,051 | $16,580,809 | +$303,012 | $6.90 | 19 |
| 2023 Q2 | 2,352,300 | $19,044,605 | +$5,865,507 | $9.14 | 18 |
| 2023 Q1 | 1,680,901 | $2,687,500 | -$78,110 | $1.60 | 14 |
| 2022 Q4 | 1,729,786 | $2,748,707 | -$3,027,635 | $1.59 | 17 |
| 2022 Q3 | 2,028,914 | $18,733,000 | -$1,898,373 | $9.24 | 23 |
| 2022 Q2 | 2,269,165 | $7,508,000 | +$7,508,000 | $3.31 | 20 |